Treatment guidelines – Treatment access

Oliviu Pascu

Treatment of chronic hepatitis C in Romania

- 2003-2015: Interferon based treatment
- 2016: Treatment of compensated cirrhosis with DAA
- 2017: Treatment of chronic hepatitis (F3), compensated cirrhosis (F4) and decompensated cirrhosis with DAA.



2000- 5000 patients /year
Hepatitis F2-F3-F4
Selected centers –Central Committee for approval

I. Interferon based terapy

No of patients	Severity assessment	SVR	nonresponders
56 000	Liver biopsy	48-50%	~30 000

II.2016-Compensated Cirrhosis Ombitasvir+Paritaprevir+ Ritonavir + Dasabuvir

No patients	Severity assesment		prescribing physicians
6000	LB- Fibromax	› 99%	11 centers (G-ID)

III. 2017-Chronic Hepatitis (f3)-compensated cirrhosis(f4) (Ombitasvir+Paritaprevir+ Ritonavir + Dasabuvir)

No of approved patients	No of treated patients	SVR	prescribing physicians
10 000	7000	99%	11 centers (G+ID)

III.2017-Decompensated cirrhosis (Sofosbuvir+Ledipasvir)

No of approved patients	No of treated patients	SVR	prescribing physicians
2000	700	90-95%	11 centers (G)

The future: 2018-2019

- We asked MH to change the low- cost-volume- because we only had one molecule available. The low was changed- and probably we will have 2 or 3 molecules(combination)
- We intend to include patients with F1 and F2 without discrimination.
- We intend to recommend the extensive use of non-invasive and inexpensive assessment methods: Fibroscan, APRI
- We want to extend the area of prescriptions to all county hospitals
- We intend to make a simple and easy to apply Protocol

EASL-2016

hepatocellular carcinoma (HCC). The number of chronically infected persons worldwide is estimated to be about <u>180 million</u>.

Where 110 million disappeared in 2 years?

EASL-2018

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately <u>71</u> million chronically infected individuals worldwide. Clinical care for patients with

It's the same situation in Romania?

- We had 30000 non-responders in 2015
- We found only 13,000 patients(2016-2017) to be included in treatment
- 17,000 have disappeared
- If the proportion remains, we may have only 150,000 to 200,000 infected patients not 500,000- 600,000
- This requires adaptation of the screening and treatment strategy.

Thank you very much